Minerva Neurosciences (NERV)

• Market cap: $27.1M
• 1 day: -4.9%
• 5 days: 1.31%
• 1 month: -3%
• 3 months: 77.98%
• 6 months: 116.76%
• Year to date: 68.7%
• 1 year: 75.57%
• 5 years: -81.7%
• 10 years: -90%
• Sector: Healthcare
• Industry: Biotechnology

About: Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Employees: 8